A Prospective, Multicenter, Randomized Trial of YINYI? Polymer-Free Paclitaxel-Eluting Stent vs. Durable Polymer Sirolimus-Eluting Stent in the Treatment of Coronary Artery Disease (FREEDOM)


Principal Investigator: Yong Huo, MD, Peking University First Hospital
CRO: CCRF (Beijing) Inc.
Data Statistics Department: Department of Biostatistics, NCCD
Sponsor: Liaoning Biomedical Materials R&D Center Co., Ltd.


YINYI? Polymer-free Paclitaxel-Eluting Coronary Stent
Durable Polymer Sirolimus-Eluting Coronary Stent (Cypher, Firebird 2, Partner)


1626 patients in all
YINYI polymer-free PES vs. Durable polymer SES = 2:1

Primary Endpoint

Target Vessel Failure (TVF) at 1 year
TVF = Target-vessel related death + MI + TVR

Secondary Endpoints

1) Definite/Probable stent thrombosis according to ARC (early, late, very late)
2) MACE at 30d, 1yr, 2yrs
3) All death, cardiac death at 30d, 1yr, 2yrs
4) Composite safety endpoint (cardiac death, MI, CVA) at 30d, 1yr, 2yrs
5) TVR, TLR at 30d, 1yr, 2yrs

Clinical Results

As the first large-scale randomized trial of the polymer-free paclitaxel-eluting stent compared to the durable polymer sirolimus-eluting stents, the results at 1-year follow-up demonstrated: there is no significant difference in primary endpoint TVF, and also no significant difference in secondary endpoints TVR, stent thrombosis and composite safety endpoint. FREEDOM proved polymer-free stent is not only safe in long-term, but also efficacy.

上海十一选五最新开奖结果 股票涨跌由什么决定视频 徐翔早期3万炒股手法 山西十一选五平台 真钱手机客户端棋牌 北京pk拾预测排行 黑龙江11元五开奖结果 云南快乐10分中奖规则金额 内蒙体彩11先5开奖号码 股票分析师考试 1山东十一选五体彩 浙江一定牛快乐12走势图 极速时时彩网站官网 山东11选五任2免费计划 云南期货配资公司 四川快乐12遗漏遗漏 哪个时时彩平台有体验金